Pyxis Oncology Inc (NASDAQ: PYXS) is 104.44% higher on its value in year-to-date trading and has touched a low of $1.35 and a high of $6.85 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The PYXS stock was last observed hovering at around $3.66 in the last trading session, with the day’s gains setting it 0.02%.
Currently trading at $3.68, the stock is 0.99% and 3.81% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.88 million and changing 0.55% at the moment leaves the stock -2.04% off its SMA200. PYXS registered 97.85% gain for a year compared to 6-month loss of -32.23%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 3.66% gain in the last 1 month and extending the period to 3 months gives it a 8.88%, and is 1.10% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.14% over the week and 5.23% over the month.
Pyxis Oncology Inc (PYXS) has around 50 employees, a market worth around $218.67M and $16.15M in sales. Profit margin for the company is -366.67%. Distance from 52-week low is 172.59% and -46.28% from its 52-week high. The company has generated returns on investments over the last 12 months (-31.27%).
The EPS is expected to grow by 45.05% this year
108.0 institutions hold shares in Pyxis Oncology Inc (PYXS), with institutional investors hold 69.10% of the company’s shares. The shares outstanding are 59.42M, and float is at 46.71M with Short Float at 8.15%. Institutions hold 55.39% of the Float.
The top institutional shareholder in the company is DEEP TRACK CAPITAL, LP with over 4.18 million shares valued at $13.85 million. The investor’s holdings represent 8.1578 of the PYXS Shares outstanding. As of 2024-06-30, the second largest holder is LAURION CAPITAL MANAGEMENT LP with 3.86 million shares valued at $12.78 million to account for 7.5282 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 2.79 million shares representing 5.4317 and valued at over $9.22 million, while BALYASNY ASSET MANAGEMENT L.P. holds 4.997 of the shares totaling 2.56 million with a market value of $8.48 million.
Pyxis Oncology Inc (PYXS) Insider Activity
The most recent transaction is an insider purchase by Connealy Pamela Ann, the company’s CFO and COO. SEC filings show that Connealy Pamela Ann bought 8,000 shares of the company’s common stock on Sep 28 ’23 at a price of $1.87 per share for a total of $14960.0. Following the purchase, the insider now owns 0.82 million shares.
Pyxis Oncology Inc disclosed in a document filed with the SEC on Sep 27 ’23 that Wadhane Jitendra (Chief Accounting Officer) bought a total of 2,500 shares of the company’s common stock. The trade occurred on Sep 27 ’23 and was made at $1.87 per share for $4675.0. Following the transaction, the insider now directly holds 0.23 million shares of the PYXS stock.
Still, SEC filings show that on Sep 27 ’23, Connealy Pamela Ann (CFO and COO) acquired 6,426 shares at an average price of $1.85 for $11868.0. The insider now directly holds 810,532 shares of Pyxis Oncology Inc (PYXS).
